Pfizer: A key study evaluating the treatment of moderate alopecia areata with Rituflo is scheduled to begin in 2026.

Zhitongcaijing · 2d ago
Pfizer: A key study evaluating the treatment of moderate alopecia areata with Rituflo is scheduled to begin in 2026.